TAIMARIS MAS MARANTE: Open Payments
NPI 1568248748 · TAMPA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,012 in 94 payments from 14 companies in 2025. Trend: 2023 $752 · 2024 $3,355 · 2025 $2,012
Food & beverage: $1,900Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 31 | $493 |
| Vanda Pharmaceuticals Inc. | 9 | $244 |
| ABBVIE INC. | 11 | $222 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $150 |
| Lundbeck LLC | 5 | $133 |
| Eisai Inc. | 1 | $122 |
| Otsuka America Pharmaceutical, Inc. | 4 | $112 |
| Janssen Pharmaceuticals, Inc | 5 | $104 |
| E.R. Squibb & Sons, L.L.C. | 5 | $90 |
| Noven Therapeutics, LLC | 5 | $80 |
Products named: AUSTEDO XR, VRAYLAR, HETLIOZ, REXULTI, CAPLYTA, Leqembi, COBENFY, Xelstrym.
Industry payments across FL — which companies pay providers there.
